Bond.az White LogoBond.az Black Logo

GE Aerospace Defense Outlook Boosts Stock Rating

RBC Capital praises GE Aerospace's defense outlook, reiterating Outperform rating. Read about strong earnings and new contracts.

Benjamin Moore
ByBenjamin Moore- Senior Editor
|
0

Bond.az - RBC Capital reiterated an Outperform rating on GE Aerospace (NYSE:GE) with a $355.00 price target, following the company's Defense & Propulsion Technologies Showcase.

GE Aerospace provided a positive outlook for revenues and margins in its DPT segment, citing services, international mix, cost actions, and pricing as drivers.

The defense business is experiencing strong tailwinds, bookings strength, and market positioning that support growth above GE's prior medium-term guidance. RBC Capital noted the segment's performance exceeds expectations.

RBC Capital stated the defense business remains under-appreciated by investors and could be a source of upside for the company.

Market sentiment on GE Aerospace continues to focus on the Commercial Engines & Services outlook. RBC Capital maintained its Outperform rating and $355 price target.

In other recent news, GE Aerospace reported strong Q1 earnings: non-GAAP EPS of $1.86 beat consensus of $1.60, and adjusted revenue of $11.61 billion topped expectations of $10.69 billion. Bernstein SocGen Group reiterated an Outperform rating and $405 target. Additionally, GE Aerospace secured a U.S. Air Force contract for preliminary design review of its GE426 engine.

Meanwhile, UBS lowered its price target to $350 from $357 due to geopolitical concerns, but maintained a Buy rating. Morgan Stanley adjusted its target to $400 from $425, keeping an Overweight rating. GE Aerospace's CEO is also set to join a U.S. delegation to China.

This article was generated with AI support and reviewed by an editor. For more information see our T&C.

More News
Today / 12:11
|
261

BMO Raises Israel Chemicals Target Price on Potash

BMO Capital raises Israel Chemicals price target to $6.50 on strong potash outlook and higher EBITDA guidance.

0
Today / 12:10
|
222

Cantor Fitzgerald raises PANW price target to $285

Cantor Fitzgerald raises Palo Alto Networks price target to $285, citing platformization, AI tailwinds, and strong partner results.

0
Today / 11:53
|
435

Stifel Maintains Manhattan Associates Price Target

Stifel maintains Buy rating and $200 target for Manhattan Associates. The company is investing in cloud migration and agentic AI capabilities.

0
Today / 11:52
|
256

Rosenblatt Raises 8x8 Target to $3.00

Rosenblatt raises 8x8 stock target to $3.00 after strong Q4 results. Revenue beat guidance.

0
Today / 11:52
|
385

Piper Sandler Reiterates Alphabet Overweight on AI

Piper Sandler reiterates Alphabet Overweight rating and $425 target after Google I/O AI product launches.

0
Today / 11:51
|
464

Rosenblatt Cuts Canaan Target Price to $1.30

Rosenblatt cuts Canaan stock price target to $1.30 from $2.25, maintains Buy rating. Canaan faces revenue miss in Q1 FY2026.

0
Today / 11:50
|
872

Bernstein raises Dell target to $280 on AI

Bernstein raises Dell price target to $280, citing agentic AI demand and SMCI share losses.

0
Today / 11:43
|
228

Alpha Tau Stock Gets Buy Rating, $15 Target

H.C. Wainwright reiterates Buy on Alpha Tau stock with $15 target. Company completes ReSTART trial enrollment.

0
Today / 11:42
|
472

H.C. Wainwright Reiterates Protara Buy Rating

H.C. Wainwright reiterates Buy rating on Protara Therapeutics (TARA) with $27 target. Encouraging results from lymphatic malformation and bladder cancer trials.

0
Today / 11:41
|
612

H.C. Wainwright reiterates MindWalk stock rating on platform validation

H.C. Wainwright reiterates Buy rating and $5 target on MindWalk stock, citing platform validation and strong pipeline. Read more.

0
Today / 11:40
|
376

Traws Pharma Gets $8 Price Target from H.C. Wainwright

H.C. Wainwright reaffirms Buy on Traws Pharma with $8 target. Financing secured for influenza drug trial. Read more on Bond.az.

0
Today / 11:33
|
665

Morgan Stanley raises ZTO target to $30.10

Morgan Stanley raises ZTO Express price target to $30.10 from $28.50, maintains Overweight rating, citing profit growth outlook.

0
...